| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(15)70102-6 |
| P698 | PubMed publication ID | 25864104 |
| P50 | author | Jean-Yves Blay | Q37842284 |
| Armando Santoro | Q56335956 | ||
| Nicolas Penel | Q56381073 | ||
| Emmanuelle Bompas | Q89340670 | ||
| George D Demetri | Q96229532 | ||
| Nicolas Isambert | Q114440231 | ||
| Sant P Chawla | Q114447881 | ||
| Didier Cupissol | Q114725572 | ||
| Arthur P Staddon | Q116794138 | ||
| Zsuzsanna Pápai | Q116794186 | ||
| P2093 | author name string | Anthony W Tolcher | |
| Fabio A Franke | |||
| Antonio López-Pousa | |||
| Antoine Italiano | |||
| Esma Saâda-Bouzid | |||
| Solenn Le-Guennec | |||
| Patrick Cohen | |||
| Nada Babovic | |||
| P2860 | cites work | Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity | Q33248747 |
| The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents | Q34122191 | ||
| The power of the Mantel-Haenszel test for grouped failure time data | Q34336459 | ||
| Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. | Q34607838 | ||
| Increasing incidence rates of soft tissue sarcomas? A population-based epidemiologic study and literature review | Q34613152 | ||
| Cediranib for metastatic alveolar soft part sarcoma | Q34651131 | ||
| Malignant vascular tumors--an update | Q34658662 | ||
| Soft tissue sarcoma, version 2.2014. | Q34661218 | ||
| Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34664479 | ||
| Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas | Q34729354 | ||
| Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). | Q36287729 | ||
| Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas | Q36622330 | ||
| Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors | Q36972860 | ||
| Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. | Q37181235 | ||
| Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. | Q37278365 | ||
| Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor | Q37756484 | ||
| Appraising the current role of chemotherapy for the treatment of sarcoma | Q37953072 | ||
| Clinicopathologic considerations: how can we fine tune our approach to sarcoma? | Q37953073 | ||
| Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis | Q38602109 | ||
| Endostar enhances the antineoplastic effects of combretastatin A4 phosphate in an osteosarcoma xenograft | Q39479278 | ||
| Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future | Q39743562 | ||
| Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. | Q40385211 | ||
| Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo | Q44412196 | ||
| Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. | Q46054785 | ||
| Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours | Q46167877 | ||
| Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. | Q50957822 | ||
| Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. | Q52625890 | ||
| Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. | Q52641965 | ||
| DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer. | Q52650698 | ||
| A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. | Q55241476 | ||
| Cisplatin. A phase II evaluation in previously untreated patients with soft tissue sarcomas | Q69745434 | ||
| Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas | Q70092359 | ||
| Determination of vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas and the role of overexpression in leiomyosarcoma | Q79255416 | ||
| Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen | Q84539941 | ||
| An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas | Q84840694 | ||
| P433 | issue | 5 | |
| P921 | main subject | placebo | Q269829 |
| cisplatin | Q412415 | ||
| ifosfamide | Q418560 | ||
| chemotherapy | Q974135 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 531-540 | |
| P577 | publication date | 2015-04-08 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial | |
| P478 | volume | 16 |
| Q26741817 | A Systematic Literature Review of Adverse Events Associated with Systemic Treatments Used in Advanced Soft Tissue Sarcoma |
| Q36673516 | Assessing the Eventual Publication of Clinical Trial Abstracts Submitted to a Large Annual Oncology Meeting |
| Q38771789 | Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study |
| Q92704134 | Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review |
| Q47726553 | Computational Design and Synthesis of Novel Fluoro-Analogs of Combretastatins A-4 and A-1. |
| Q36839418 | Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents |
| Q98906688 | Dose-response assessment by quantitative MRI in a phase 1 clinical study of the anti-cancer vascular disrupting agent crolibulin |
| Q48893627 | ECBS & ICBS 2015 Joint Meeting: Bringing Chemistry to Life |
| Q53175509 | Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. |
| Q90446063 | Ifosfamide, Carboplatin, and Etoposide (ICE) in Combination with Regional Hyperthermia as Salvage Therapy in Patients with Locally Advanced Nonmetastatic and Metastatic Soft-Tissue Sarcoma |
| Q38952778 | Microtubule destabilising agents: far more than just antimitotic anticancer drugs |
| Q52674608 | Phase 1 study of ombrabulin in combination with cisplatin (CDDP) in Japanese patients with advanced solid tumors. |
| Q64262864 | Phase I and phase II clinical trials in sarcoma: Implications for drug discovery and development |
| Q37716872 | Phase III Soft Tissue Sarcoma Trials: Success or Failure? |
| Q36844333 | Rapid induction of apoptosis in chronic lymphocytic leukemia cells by the microtubule disrupting agent BNC105. |
| Q36009462 | Review of the Reporting of Survival Analyses within Randomised Controlled Trials and the Implications for Meta-Analysis |
| Q38611179 | Salvage Therapy in Advanced Adult Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis of Randomized Trials |
| Q26781365 | Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option? |
| Q55365628 | Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. |
| Q44501064 | Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization. |
| Q52659096 | Tumour vascular-disrupting agents in soft-tissue sarcoma. |
| Q90344247 | Update on systemic therapy for advanced soft-tissue sarcoma |
Search more.